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BACKGROUND
An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that 
depleting B cells could be useful for treatment. We studied ocrelizumab, a humanized 
monoclonal antibody that selectively depletes CD20-expressing B cells, in the primary 
progressive form of the disease.
METHODS
In this phase 3 trial, we randomly assigned 732 patients with primary progressive mul-
tiple sclerosis in a 2:1 ratio to receive intravenous ocrelizumab (600 mg) or placebo every 
24 weeks for at least 120 weeks and until a prespecified number of confirmed disability 
progression events had occurred. The primary end point was the percentage of patients 
with disability progression confirmed at 12 weeks in a time-to-event analysis.
RESULTS
The percentage of patients with 12-week confirmed disability progression was 32.9% with 
ocrelizumab versus 39.3% with placebo (hazard ratio, 0.76; 95% confidence interval [CI], 
0.59 to 0.98; P = 0.03). The percentage of patients with 24-week confirmed disability pro-
gression was 29.6% with ocrelizumab versus 35.7% with placebo (hazard ratio, 0.75; 95% 
CI, 0.58 to 0.98; P = 0.04). By week 120, performance on the timed 25-foot walk worsened 
by 38.9% with ocrelizumab versus 55.1% with placebo (P = 0.04); the total volume of brain 
lesions on T2-weighted magnetic resonance imaging (MRI) decreased by 3.4% with 
ocrelizumab and increased by 7.4% with placebo (P<0.001); and the percentage of brain-
volume loss was 0.90% with ocrelizumab versus 1.09% with placebo (P = 0.02). There was 
no significant difference in the change in the Physical Component Summary score of the 
36-Item Short-Form Health Survey. Infusion-related reactions, upper respiratory tract in-
fections, and oral herpes infections were more frequent with ocrelizumab than with 
placebo. Neoplasms occurred in 2.3% of patients who received ocrelizumab and in 0.8% 
of patients who received placebo; there was no clinically significant difference between 
groups in the rates of serious adverse events and serious infections.
CONCLUSIONS
Among patients with primary progressive multiple sclerosis, ocrelizumab was associ-
ated with lower rates of clinical and MRI progression than placebo. Extended observa-
tion is required to determine the long-term safety and efficacy of ocrelizumab. (Funded 
by F. Hoffmann–La Roche; ORATORIO ClinicalTrials.gov number, NCT01194570.)
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Primary progressive multiple scle-rosis accounts for 10 to 15% of the overall population with multiple sclerosis.1 The 
course of this disease differs from those of re-
lapsing–remitting and secondary progressive 
forms of multiple sclerosis in that progression 
consists mainly of gradual worsening of neuro-
logic disability from symptom onset, although 
relapses may occur.1 Phase 3 trials in primary 
progressive multiple sclerosis have been unsuc-
cessful,2-4 and no disease-modifying treatments 
have been approved.
B cells contribute to the pathogenesis of mul-
tiple sclerosis, including the primary progressive 
form.5 Although the mechanisms of tissue injury 
in multiple sclerosis are uncertain, B cells may 
influence pathogenesis through antigen presen-
tation,6 autoantibody production,7,8 or cytokine 
secretion.6 B cells are present in meningeal in-
flammation, which is characteristic of chronic 
multiple sclerosis and may cause adjacent corti-
cal demyelinating and neurodegenerative patho-
logic features.9,10CD20 is a cell-surface antigen 
found on pre-B cells and mature and memory 
B cells but not on the earliest B-cell precursors 
or on plasma cells.11-13 Ocrelizumab is a human-
ized monoclonal antibody that selectively depletes 
CD20-expressing B cells14,15 while preserving the 
capacity for B-cell reconstitution and preexisting 
humoral immunity.16,17
A previous phase 2–3 trial of the chimeric 
monoclonal anti-CD20 antibody rituximab 
(OLYMPUS trial) in primary progressive multiple 
sclerosis did not meet its primary efficacy end 
point, but a subgroup analysis showed delayed 
progression of disability in younger patients (<51 
years of age) with evidence of increased inflam-
matory disease activity.3 Those results provided 
the rationale and in part informed the trial design 
for this investigation of ocrelizumab in patients 
with primary progressive multiple sclerosis. Here, 
we report results from a phase 3, randomized, 
parallel-group, double-blind, placebo-controlled 
trial (ORATORIO) that investigated the efficacy 
and safety of ocrelizumab in patients with pri-
mary progressive multiple sclerosis.
Me thods
Trial Oversight
The sponsor, F. Hoffmann–La Roche, designed 
the trial in consultation with members of the 
ORATORIO trial steering committee. Data were 
collected by the investigators and analyzed by the 
sponsor; the results were reviewed by the spon-
sor and steering committee. An independent data 
and safety monitoring committee reviewed safety 
data on an ongoing basis and provided guidance 
on trial continuation, modification, or termina-
tion. (See the trial oversight section in the Sup-
plementary Appendix, available with the full text 
of this article at NEJM.org.) All authors partici-
pated in the writing of the manuscript and ap-
proved the draft that was submitted for publica-
tion. The first draft of the manuscript was written 
by the first and last authors, with medical writing 
assistance funded by the sponsor. The authors 
vouch for the accuracy and completeness of the 
data and data analyses and for the fidelity of 
the trial to the protocol (available at NEJM.org). 
The trial was conducted in accordance with the 
provisions of the International Conference on 
Harmonisation Guidelines for Good Clinical 
Practice18 and the Declaration of Helsinki.19
Patients
Key eligibility criteria were an age of 18 to 55 years, 
a diagnosis of primary progressive multiple sclero-
sis (according to the 2005 revised McDonald crite-
ria),20 a score on the Expanded Disability Status 
Scale (EDSS) of 3.0 to 6.5 at screening (range, 0 to 
10.0, with higher scores indicating greater disabil-
ity),21 a score on the pyramidal functions compo-
nent of the Functional Systems Scale of at least 
2 (range, 0 to 6, with higher scores indicating 
greater disability), a duration of multiple sclero-
sis symptoms of less than 15 years in patients 
with an EDSS score of more than 5.0 at screen-
ing or less than 10 years in patients with an EDSS 
score of 5.0 or less at screening, and a documented 
history or the presence at screening of an elevated 
IgG index or at least one IgG oligoclonal band 
detected in the cerebrospinal fluid. Key exclusion 
criteria were a history of relapsing–remitting, 
secondary progressive, or progressive relapsing 
multiple sclerosis; contraindications to magnetic 
resonance imaging (MRI); contraindications to 
or unacceptable side effects from oral or intrave-
nous glucocorticoids; and previous treatment with 
B-cell–targeted therapies and other immunosup-
pressive medications, as defined in the protocol.
Trial Design
Patients were randomly assigned in a 2:1 ratio to 
receive 600 mg of ocrelizumab by intravenous 
infusion (administered as two 300-mg infusions 
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14 days apart) or matching placebo every 24 weeks 
(Fig. S1 in the Supplementary Appendix). The trial 
was event-driven, such that double-blind treatment 
was administered for a minimum of five doses 
(120 weeks) until the occurrence in the trial co-
hort of approximately 253 events of disability pro-
gression that was confirmed for at least 12 weeks. 
Early enrollees in the trial received more than 
five double-blind doses, dependent on the time 
of enrollment and the number of confirmed dis-
ability progression events that had occurred 
(Table S1 in the Supplementary Appendix). All 
patients received intravenous methylprednisolone 
(100 mg) before infusion. Optional prophylaxis 
with analgesics or antipyretics and antihistamine 
was recommended before infusion, and adjust-
ment of the infusion rate and symptomatic treat-
ment during infusion were permitted to manage 
infusion-related reactions.
Randomization that was stratified according 
to geographic region and age was performed cen-
trally by an independent interactive Web-response 
system. Each trial center had separate treating and 
examining investigators. An independent, trained 
investigator who was unaware of the trial-group 
assignments and was certified in administering 
the EDSS conducted the neurologic examination 
and scored the EDSS. EDSS assessment and data 
collection were captured with the use of a real-
time, electronic tablet data-entry system. Multi-
ple Sclerosis Functional Composite analysis was 
performed by the examining investigator or a 
qualified designee who was unaware of the trial-
group assignments. MRI scans were analyzed 
independently at a central MRI reading center by 
staff members who were unaware of the trial-
group assignments. (See the section on additional 
methodologic details in the Supplementary Ap-
pendix.)
Patients who completed the blinded treatment 
phase were eligible to enter the open-label exten-
sion phase of the trial, after the database lock and 
unblinding of trial results. Patients who discon-
tinued prematurely or who did not wish to enter 
the open-label extension phase were included in 
the safety follow-up.
Trial End Points
The primary end point was the percentage of 
patients with disability progression confirmed at 
12 weeks in a time-to-event analysis, in which 
disability progression was defined as an increase 
in the EDSS of at least 1.0 point from baseline 
that was sustained on subsequent visits for at 
least 12 weeks if the baseline score was 5.5 or 
less or an increase of at least 0.5 points that was 
sustained for at least 12 weeks if the baseline 
score was more than 5.5. If the primary end point 
reached a significance level of P<0.05, secondary 
end points were tested in the following hierar-
chical order as long as each preceding end point 
reached a significance level of P<0.05: the per-
centage of patients with disability progression 
confirmed at 24 weeks in a time-to-event analy-
sis, change in performance on the timed 25-foot 
walk from baseline to week 120, change in the 
total volume of brain lesions on T2-weighted MRI 
from baseline to week 120, change in brain vol-
ume from week 24 to week 120, and change in 
the Physical Component Summary score of the 
Medical Outcomes Study 36-Item Short-Form 
Health Survey (SF-36), version 2, from baseline 
to week 120 (range, 0 to 100, with higher scores 
indicating better physical-health–related quality 
of life. Drug safety and adverse events were also 
analyzed. There were 16 exploratory end points, 
including the time to onset of 12-week and 24-week 
confirmed composite disability progression (de-
fined as the first confirmed occurrence of an in-
crease in the EDSS score, an increase in the time 
to perform the timed 25-foot walk of ≥20%, or 
an increase in the time to complete the 9-hole peg 
test of ≥20%), time to a sustained increase of at 
least 20% in performance on the timed 25-foot 
walk, time to a sustained increase of at least 20% 
in the 9-hole peg test, total number of new or 
enlarging lesions on T2-weighted images from 
baseline to week 120, and pharmacokinetics, im-
munogenicity, and pharmacodynamics of ocreliz-
umab.
Statistical Analysis
All efficacy end points were analyzed in the inten-
tion-to-treat population (all randomly assigned 
patients). The time to confirmed disability pro-
gression was analyzed with the use of a two-sided 
log-rank test for differences between the ocreliz-
umab and placebo groups that was stratified 
according to region (United States vs. rest of the 
world) and age (≤45 vs. >45 years) at baseline; a 
P value of less than 0.05 was considered to indi-
cate statistical significance. Cox regression was 
used for estimation of hazard ratios. The sample 
size was based on an estimated rate of 12-week 
confirmed disability progression of 0.30 for the 
ocrelizumab group and 0.43 for the placebo group 
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over a period of 2 years (hazard ratio, 0.64). With 
a 2:1 ratio for randomization between the ocre-
lizumab and placebo groups, using a two-sided 
log-rank test, we calculated that a total sample 
of 630 patients would provide 80% statistical 
power to maintain a type I error rate of 0.01, 
assuming a dropout rate of approximately 20%. 
For the primary and first secondary efficacy end 
points (i.e., confirmed disability progression that 
was sustained for ≥12 weeks and ≥24 weeks, re-
spectively), patients with missing data on the EDSS 
score at baseline were excluded from the analy-
sis, and patients with an initial disability progres-
sion during the blinded treatment period who 
discontinued ocrelizumab or placebo early and 
did not have a subsequent visit with confirmatory 
measurement of the EDSS score were considered 
to have confirmed disability progression (Table 
S2 in the Supplementary Appendix). Hierarchical 
testing of each secondary efficacy end point was 
performed. (For details, see the Statistical Anal-
ysis section in the Supplementary Appendix.)
Data for the timed 25-foot walk and the vol-
ume of lesions on T2-weighted images often are 
not normally distributed, with potentially extreme 
outlier values. Therefore, the use of the ranked 
analysis of covariance (ANCOVA) method was pre-
specified to perform robust hypothesis testing. 
Missing values were imputed by means of the 
last-observation-carried-forward method. To pro-
vide estimates of expected change from baseline 
and treatment effect, we used a mixed-effect 
model repeated measure (MMRM) approach that 
was based on log-transformed data. Log trans-
formation was predicted to approximately normal-
ize data on the basis of experience from phase 3 
studies of relapsing multiple sclerosis and from 
assessment of the distributions for timed 25-foot 
walk and the volume of lesions on T2-weighted 
images within the blinded ORATORIO data. For 
brain volume, P values and estimates were based 
on MMRM analysis of percent change from base-
line. Ranked ANCOVA and MMRM analyses were 
adjusted for baseline values, geographic region, 
and age.
R esult s
Patients
From March 3, 2011, through December 27, 2012, 
a total of 732 patients underwent randomization 
(intention-to-treat population); 488 were assigned 
to receive ocrelizumab and 244 to receive place-
bo. Baseline demographic and disease character-
istics were balanced between the trial groups 
(Table 1). A total of 402 patients (82%) who were 
assigned to ocrelizumab and 174 (71%) assigned 
to placebo reached 120 weeks in the trial. A total 
of 549 patients (387 [79%] assigned to ocrelizu-
mab and 162 [66%] assigned to placebo) were 
still receiving the blinded trial agent when the 
prespecified number of primary-outcome events 
was attained to designate the clinical cutoff date 
for the double-blind phase of the trial (Fig. S2 in 
the Supplementary Appendix). The median trial 
duration was 2.9 years in the ocrelizumab group 
and 2.8 years in the placebo group.
Efficacy
Clinical End Points
The percentage of patients with 12-week con-
firmed disability progression (primary end point) 
was 32.9% with ocrelizumab versus 39.3% with 
placebo (hazard ratio, 0.76; 95% confidence in-
terval [CI], 0.59 to 0.98; relative risk reduction, 
24%; P = 0.03) (Table 2 and Fig. 1A). The percent-
age of patients with 24-week confirmed disabil-
ity progression (first secondary end point in the 
analysis hierarchy) was 29.6% with ocrelizumab 
and 35.7% with placebo (hazard ratio, 0.75; 95% 
CI, 0.58 to 0.98; relative risk reduction, 25%; 
P = 0.04) (Table 2 and Fig. 1B). The mean change 
from baseline to week 120 in performance on 
the timed 25-foot walk (second secondary end 
point) was 38.9% with ocrelizumab versus 55.1% 
with placebo (relative reduction with ocrelizumab, 
29.3%; 95% CI, –1.6 to 51.5; P = 0.04) (Table 2). 
There was no significant between-group differ-
ence in the change in the SF-36 Physical Compo-
nent Summary score from baseline to week 120 
(fifth secondary end point; adjusted mean change, 
–0.7 with ocrelizumab and –1.1 with placebo;
P = 0.60) (Table 2).
The results of sensitivity analyses of the pri-
mary end point and first secondary end point that 
evaluated the influence of physician-reported 
clinical relapses or protocol-defined relapses on 
disability-progression data were consistent with 
the primary results, as were the results of sensi-
tivity analyses that used alternative imputation 
approaches for patients with initial disability pro-
gression (Tables S4 and S10 in the Supplementary 
Appendix). The result of a subgroup analysis of 
efficacy end points in patients with and without 
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gadolinium-enhancing lesions on T1-weighted 
images at baseline was directionally consistent 
with the findings in the overall trial population. 
The trial was not powered to show between-group 
differences among these subgroups (Table S5 in 
the Supplementary Appendix). Whether signs of 
active inflammation at baseline might represent 
a potential treatment-effect–modifying factor re-
mains to be further elucidated.
Several exploratory end points with direct bear-
ing on the primary analysis were analyzed (Table 
S3 and Figs. S3 and S4 in the Supplementary 
Characteristic
Ocrelizumab 
(N = 488)
Placebo 
(N = 244)
Age — yr
Mean 44.7±7.9 44.4±8.3
Median (range) 46.0 (20–56) 46.0 (18–56)
Female sex — no. (%) 237 (48.6) 124 (50.8)
Time since onset of MS symptoms — yr†
Mean 6.7±4.0 6.1±3.6
Median (range) 6.0 (1.1–32.9) 5.5 (0.9–23.8)
Time since diagnosis of PPMS — yr‡
Mean 2.9±3.2 2.8±3.3
Median (range) 1.6 (0.1–16.8) 1.3 (0.1–23.8)
No previous use of disease-modifying therapy — no. (%)§ 433 (88.7) 214 (87.7)
Score on EDSS¶
Mean 4.7±1.2 4.7±1.2
Median (range) 4.5 (2.5–7.0) 4.5 (2.5–6.5)
Gadolinium-enhancing lesions on T1-weighted images  
— no./total no. (%)
Yes‖ 133/484 (27.5) 60/243 (24.7)
No 351/484 (72.5) 183/243 (75.3)
No. of lesions on T2-weighted images**
Mean 48.7±38.2 48.2±39.3
Median (range) 42.0 (0–249.0) 43.0 (0–208.0)
Total volume of lesions on T2-weighted images — cm3**
Mean 12.7±15.1 10.9±13.0
Median (range) 7.3 (0–90.3) 6.2 (0–81.1)
Normalized brain volume — cm3††
Mean 1462.9±84.0 1469.9±88.7
Median (range) 1462.2 (1214.3–1711.1) 1464.5 (1216.3–1701.7)
*  Plus–minus values are means ±SD. Patients were stratified according to geographic region (United States vs. rest of
the world) and age (≤45 vs. >45 years). MS denotes multiple sclerosis, and PPMS primary progressive MS.
†  Data were not available for 14 patients in the ocrelizumab group and 7 patients in the placebo group.
‡  Data were not available for 2 patients in the ocrelizumab group and 1 patient in the placebo group.
§  Shown are data for patients with no use of disease-modifying therapy in the 2 years before trial entry.
¶  Scores on the Expanded Disability Status Scale (EDSS) range from 0 to 10, with higher scores indicating greater dis-
ability. Data were not available for 1 patient in the ocrelizumab group.
‖  A breakdown of the categorical numbers of gadolinium-enhancing lesions on T1-weighted images is provided in Table 
S7 in the Supplementary Appendix.
**  Data were not available for 2 patients in the ocrelizumab group and 1 patient in the placebo group.
††  The analysis was performed with the use of SIENA/X.22 Data were not available for 6 patients in the ocrelizumab 
group and 1 patient in the placebo group.
Table 1. Baseline Demographic and Disease Characteristics (Intention-to-Treat Population).*
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Figure 1. Primary and Key Secondary Clinical Outcomes (Intention-to-Treat Population).
Panel A (primary end point) and Panel B (first secondary end point) show the cumulative probability of clinical dis-
ability progression (as defined by an increase in the score on the Expanded Disability Status Scale) that was confirmed 
after at least 12 weeks and at least 24 weeks, respectively, in time-to-event analyses. P values were calculated with 
the use of the log-rank test.
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Appendix). The prespecified exploratory analysis 
of 12-week and 24-week confirmed composite dis-
ability progression and its components signifi-
cantly favored ocrelizumab.
Brain MRI End Points
The total volume of hyperintense lesions on T2-
weighted images from baseline to week 120 (third 
secondary end point) decreased with ocrelizumab 
and increased with placebo (mean percent change, 
−3.4 vs. 7.4; P<0.001) (Table 2 and Fig. 2A). The 
adjusted mean percent change in brain volume 
from week 24 to week 120 (fourth secondary end 
point) was lower with ocrelizumab than with 
placebo (–0.90 vs. –1.09, P = 0.02) (Table 2 and 
Fig. 2B). The adjusted mean number of new or 
enlarging hyperintense lesions on T2-weighted im-
ages from baseline to week 120 (exploratory end 
point) was lower with ocrelizumab than with 
placebo (0.31 vs. 3.88, P<0.001) (Table S3 in the 
Supplementary Appendix).
Safety
Adverse Events
A total of 725 patients (486 in the ocrelizumab 
group and 239 in the placebo group) received at 
least one dose of a trial agent and were included 
in the safety analysis population. The percentage 
of patients who had at least one adverse event 
was 95.1% with ocrelizumab and 90.0% with pla-
cebo. Serious adverse events were reported among 
20.4% of those who received ocrelizumab and 
22.2% of those who received placebo (Table 3). 
Overall, the rates of adverse events per 100 pa-
tient-years did not differ significantly between the 
ocrelizumab group and the placebo group (260.5 
[95% CI, 252.2 to 269.1] and 267.0 [95% CI, 254.7 
to 279.8], respectively), with no increase over time 
or with subsequent doses. Adverse events that led 
to discontinuation of the trial agent occurred 
among 4.1% of patients who received ocrelizumab 
and 3.3% of patients who received placebo.
The most frequently reported adverse event 
among ocrelizumab-treated patients was infusion-
related reaction: 39.9% of those who received 
ocrelizumab reported at least one infusion-related 
reaction as compared with 25.5% of those who 
received placebo. More patients in the ocrelizumab 
group than in the placebo group had adverse 
events leading to modification of the infusion 
rate or interruption of infusions (9.7% vs. 5.0%). 
Two patients (0.4%) withdrew from ocrelizumab 
treatment because of infusion-related reactions. 
Infusion-related reactions decreased in both rate 
and severity with subsequent administration; none 
were fatal or life-threatening (Fig. S5 in the Sup-
plementary Appendix). The percentage of patients 
who reported upper respiratory tract infections 
was higher in the ocrelizumab group than in the 
placebo group (10.9% vs. 5.9%). Overall, five 
deaths were reported: four (0.8%) in the ocreliz-
umab group owing to pulmonary embolism, 
pneumonia, pancreatic carcinoma, and aspiration 
pneumonia and one (0.4%) in the placebo group 
owing to a road-traffic accident.
Figure 2. MRI End Points (Intention-to-Treat Population).
Panel A shows the percent change in the total volume of brain lesions on 
T2-weighted MRI from baseline to week 120 (third secondary end point). 
The P value was calculated with the use of a ranked analysis of covariance. 
Panel B shows the percent change on MRI scans in brain volume from 
week 24 to week 120 (fourth secondary end point). The P value was calcu-
lated with the use of a mixed-effect model repeated measure (MMRM) 
 approach. I bars indicate 95% confidence intervals.
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Infections
The percentage of patients reporting any infec-
tion was 71.4% in the ocrelizumab group and 
69.9% in the placebo group. The most common 
infections (i.e., with a frequency of ≥10% in one 
of the trial groups) were nasopharyngitis (22.6% 
with ocrelizumab and 27.2% with placebo), urinary 
tract infection (19.8% with ocrelizumab and 22.6% 
with placebo), influenza (11.5% with ocrelizumab 
and 8.8% with placebo), and upper respiratory 
tract infection (as noted above). The percentage 
of patients with serious infections according to 
system organ class was similar in the two groups 
(6.2% with ocrelizumab and 5.9% with placebo) 
and changed little with the use of a broader 
definition of serious infections, which included 
Event
Ocrelizumab 
(N = 486)
Placebo 
(N = 239)
Any adverse event — no. of patients (%)† 462 (95.1) 215 (90.0)
Adverse event leading to discontinuation of trial agent — 
no. of patients (%)
20 (4.1) 8 (3.3)
Death — no. of patients (%)‡ 4 (0.8) 1 (0.4)
Infusion-related reactions
≥1 Reaction — no. of patients (%) 194 (39.9) 61 (25.5)
Total no. of reactions 485 145
Grade of reaction — no. of patients (%)
1: mild 129 (26.5) 38 (15.9)
2: moderate 59 (12.1) 19 (7.9)
3: severe 6 (1.2) 4 (1.7)
4: life-threatening 0 0
5: death 0 0
Any serious adverse event — no. of patients (%) 99 (20.4) 53 (22.2)
Serious infections — no. of patients (%) 30 (6.2) 14 (5.9)
Neoplasms — no. of patients (%)§ 11 (2.3) 2 (0.8)
Breast cancer 4 (0.8)¶ 0
Basal-cell carcinoma 3 (0.6) 1 (0.4)
Adenocarcinoma of the cervix 0 1 (0.4)
Anaplastic large-cell lymphoma 1 (0.2) 0
Endometrial adenocarcinoma 1 (0.2) 0
Malignant fibrous histiocytoma 1 (0.2) 0
Metastatic pancreatic carcinoma 1 (0.2) 0
*  Adverse events were coded according to the preferred terms in the Medical Dictionary for Regulatory Activities, version
18.0. This table contains data collected up until the end of the double-blind controlled treatment period as of the clini-
cal cutoff date (July 24, 2015). For an up-to-date list of adverse events (including serious adverse events) that is based
on information available as of January 20, 2016, see Table S8 in the Supplementary Appendix. Four patients who were
assigned to the placebo group received a single dose of ocrelizumab treatment; these patients were included in the
ocrelizumab group in the safety analysis.
†  For the adverse events reported by at least 10% of the patients in either group, see Table S9 in the Supplementary 
Appendix.
‡  Deaths occurring during the trial were due to a road-traffic accident in the placebo group and pulmonary embolism, 
pneumonia, pancreatic carcinoma, and aspiration pneumonia in the ocrelizumab group.
§  For an up-to-date list of all additional neoplasms recorded in the latest extended safety follow-up analysis of all expo-
sure up until June 30, 2016 (including respective open-label extension phases) of the OPERA I trial (ClinicalTrials.gov
number, NCT01247324), OPERA II trial (NCT01412333), ORATORIO trial (NCT01194570), and phase 2 studies
(NCT00676715) of ocrelizumab in multiple sclerosis, see Table S6 in the Supplementary Appendix.
¶  Two events were coded as invasive ductal breast carcinoma and one each as breast cancer and invasive breast carcinoma.
Table 3. Adverse Events (Safety Population).*
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nonserious infections that were treated with an 
intravenous antiinfective agent (7.6% with ocre-
lizumab and 8.8% with placebo). Among all 
herpesvirus-related infections (4.7% with ocreliz-
umab and 3.3% with placebo), oral herpes was 
more common among patients who received ocrel-
izumab than among those who received placebo 
(2.3% vs. 0.4%); all cases were mild to moderate 
— that is, corresponding to grade 1 or 2 according 
to the Common Terminology Criteria for Adverse 
Events. (Additional details are provided in the 
Safety section in the Supplementary Appendix.)
Laboratory Assessments
After the first infusion of ocrelizumab, levels of 
CD4-expressing T cells remained stable through-
out the treatment period, whereas there was an 
initial mean decrease of 2 to 6% from baseline 
in peripheral-blood counts of CD3+ or CD8+ cells, 
apparent at week 2. An additional 6% decrease 
was observed from week 2 to week 120 for CD8-
expressing cells. This finding differed from a sta-
ble course of CD8-expressing cells in the placebo 
group, in which an initial 4 to 5% mean increase 
in CD3+ or CD4+ cells was observed at week 2 
and was maintained thereafter. There was no 
effect of ocrelizumab treatment on natural killer 
(CD16+ or CD56+) cells, with a mean increase of 
approximately 3% in each group from baseline 
to week 120. (Additional details on immuno-
globulin levels and antidrug antibodies are pro-
vided in the Safety section in the Supplementary 
Appendix.)
Neoplasms
Over the controlled treatment period, neoplasms 
were reported in 11 of 486 patients (2.3%) in the 
ocrelizumab group (breast cancer in 4 patients, 
basal-cell carcinoma in 3, and endometrial adeno-
carcinoma, anaplastic large-cell lymphoma [main-
ly T cells], malignant fibrous histiocytoma, and 
pancreatic carcinoma in 1 each) and in 2 of 239 
patients (0.8%) in the placebo group (cervical 
adenocarcinoma in situ and basal-cell carcinoma 
in 1 each). Between the clinical cutoff date (July 24, 
2015) and June 30, 2016, two additional cases of 
neoplasm (one case each of basal-cell skin carci-
noma and squamous-cell carcinoma) were detect-
ed during the open-label extension phase in which 
all patients received ocrelizumab. As of June 30, 
2016, the overall incidence of a first neoplasm 
among patients with multiple sclerosis who were 
treated with ocrelizumab across all studies 
(ClinicalTrials.gov numbers, NCT01247324, 
NCT01412333, NCT00676715, and NCT01194570) 
was 0.40 per 100 patient-years of exposure (6467 
patient-years of exposure) as compared with 0.20 
per 100 patient-years for pooled comparator groups 
(interferon beta-1a or placebo, 2053 patient-years 
of exposure) (Table S6 in the Supplementary Ap-
pendix).
Discussion
In this trial, the results favored ocrelizumab over 
placebo with respect to the risk of confirmed 
disability progression at 12 weeks, the primary 
end point, and the first four of five secondary end 
points: 24-week confirmed disability progression, 
ambulation speed as assessed by the timed 25-foot 
walk, change in the total volume of brain lesions 
on T2-weighted images, and change in brain vol-
ume. However, there was no significant between-
group difference in the physical component of 
the SF-36. The magnitude of the effect of ocreli-
zumab on clinical end points was similar when 
we compared the results for 12-week and 24-week 
confirmed disability progression.
Infusion-related reactions were more frequent 
among patients who received ocrelizumab than 
those who received placebo. Such reactions were 
most commonly observed with the first infusion, 
decreased with subsequent doses, and were treated 
with premedication and infusion adjustments.23
The imbalance in observed neoplasms in the 
ocrelizumab group as compared with the placebo 
group warrants ongoing evaluation in the con-
text of the epidemiology of neoplasms in the popu-
lation with multiple sclerosis and long-term ex-
perience with ocrelizumab and other anti-CD20 
treatments.24-26 No cases of progressive multifo-
cal leukoencephalopathy (PML) have been reported 
so far with ocrelizumab across all clinical studies 
of the drug, but further assessment is required to 
characterize the risk of uncommon adverse events, 
including PML.
Safety will continue to be assessed throughout 
the open-label extension phase. These data, along 
with those from other studies involving patients 
with relapsing and primary progressive multiple 
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sclerosis, may help to determine the long-term 
benefit–risk profile of ocrelizumab. As in all clini-
cal trials, caution should prevail in the expansion 
of the interpretation of trial results beyond the 
limits of the studied population and duration of 
the trial.
Pathological studies suggest that progressive-
onset multiple sclerosis is part of a spectrum of 
overlapping phenotypes.27 The efficacy of ocreliz-
umab in our trial indicates that B cells contrib-
ute to the pathogenesis of primary progressive 
multiple sclerosis and that B-cell–mediated in-
flammation has a direct or indirect role in neu-
rodegeneration.28,29
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